Dr. Donald Poirier has been a professor at the Department of Molecular Medicine (Faculty of Medicine, Laval University, Québec, Qc) since July 1991 as well as a researcher at the CHU de Québec – Research Center (Québec, Qc). Since 2008, he has also been Director of the Organic Synthesis Service and Co-Director of the Analytical and Medicinal Chemistry Platform.

Professor Poirier received his basic training in organic chemistry (PhD from Laval University, 1980-1985) and subsequently specialized in medicinal chemistry and endocrinology (Postdoctoral studies at the CHUL-Research Center, 1986-1990, CRM fellowship) and more recently in solid phase synthesis of small molecules of therapeutic interest such as steroid derivatives. He is especially interested in the development of steroidogenic enzyme (17b-HSDs, steroid sulfatase, CYP1B1) inhibitors and antitumor agents for the treatment of different cancers (breast, prostate, ovary, pancreatic, and leukemia). As examples, he developed the first non-estrogenic irreversible steroidal inhibitor of 17β-HSD1 for the treatment of breast cancer and endometriosis. He also developed a family of aminosteroid derivatives that inhibited tumor growth in mice for different cancers (breast, ovary, pancreatic, and leukemia).

In addition to the synthesis of small molecules by classical chemistry, he succeeded by developing solid-phase syntheses of C18-steroid (estrane) derivatives as well as C19-steroid (androstane) derivatives that enabled the generation of model libraries of targeted therapeutic compounds. Thus, he developed a diethylsilylacetylenic linker that produces more stable compounds and a sulfamate linker that produces two classes (phenol and sulfamate) of relevant steroidal or nonsteroidal compounds according to cleavage conditions. He is also interested in additional aspects of organic chemistry (synthesis, new methodologies, NMR analysis, etc.) and medicinal chemistry (SAR, molecular modeling, biological assays, etc.). A particularity of his research group is that he is interested in several stages of the development of a new drug: conception, chemical synthesis, in vitro biological tests (enzymatic assays, cell proliferation, etc.) and in vivo (estrogenic activities and androgenic in female and male mice, plasma concentration, metabolic stability, xenografts of cancer cells, etc.).

Professor Poirier has published 220 scientific publications and is the holder of 11 patents and patent applications. He has also been involved in more than 450 oral and poster presentations, as well as conferences as invited speaker.

CHUL
2705, boulevard Laurier
T-4-50
Québec, Québec
Canada G1V 4G2
224 entries « 23 of 23 »

Poulin R, Baker D, Poirier D, Labrie F

Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells.

Journal Article

Breast Cancer Res Treat, 13 (2), pp. 161-72, 1989, ISSN: 0167-6806.

Abstract | Links:

Poirier D, Poulin R, Labrie F

Screening of lipoidal steroid formation in the ZR-75-1 human breast cancer cell line

Book Chapter

F, Bresciani; RJB, King; ME, Lippman; JP, Raynaud (Ed.): Hormones and cancer 3: proceedings of the Third International Congress on Hormones and Cancer, pp. 384-387, New York, Raven Press, 1988, ISBN: 0881674532.

Zee JA, Poirier D, Cusson M, Roberge AG, Sévigny J

Valeurs nutritives des fruits et légumes produits et consommés au Québec

Journal Article

Canadian Institute of Food Science and Technology journal. Journal de l’Institut canadien de science et technologie alimentaire, 20 , pp. 350-356, 1987, ISSN: 0315-5463.

Savoie R, Poirier D, Prizant L, Beauchamp AL

Raman and infared spectra of crystalline 9-methyladenine and its methylmercury complexes

Journal Article

J Church State, 11 , pp. 481-486, 1981, ISSN: 0021-969X.

224 entries « 23 of 23 »
Signaler des ajouts ou des modifications

Active projects

  • 3alpha-hydroxysteroid dehydrogenase type 3 as a modulator of human adipose tissue function and distribution, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2020-04-01 to 2023-03-31
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13

Recently finished projects

  • Démonstration de l'efficacité du premier inhibiteur irréversible et sélectif de la 17beta-HSD1 pour le traitement des cancers du sein sensibles aux estrogènes, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2020-03-31
  • Développement d’un traitement sélectif de l’endométriose : Étude du potentiel du premier inhibiteur irréversible de la 17beta-HSD1 chez le primate, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2019-09-30
  • Projet de recherche dans l'axe endocrinologie et néphrologie, Subvention, Fondation du CHU de Québec, from 2019-01-30 to 2020-03-31
  • Valorisation de la technologie des aminostéroïdes par une caractérisation du mécanisme d'action , Subvention, Ministère de l'Économie et de l'Innovation, from 2019-07-05 to 2020-02-28
Data provided by the Université Laval research projects registery